A proposed Hodgkin's lymphoma treatment returned positive test results in a clinical trial, according to drugmaker Seattle Genetics Inc., which seeks to file the drug for approval with the U.S. Food and Drug Administration next year.
Roche's top-selling cancer-fighting drug Avastin has hit another roadblock in testing. In a Phase III study, Avastin failed to improve disease-free survival in early-stage colon cancer patients, the pharmaceutical giant reported.
The FDA denied accelerated approval of Roche's trastuzumab-DM1 (T-DM1) license application. T-DM1 is a potential breast cancer treatment. Roche will continue with its trials and plans a global regulatory submission in mid-2012.
